



COMPANY NEWSLETTER

July 2018

MESSAGE FROM THE MANAGING DIRECTOR



Welcome to our quarterly newsletter that wraps up the 2018 financial year. In recent editions we've been excited by progress on multiple fronts and this one is no exception – Proteomics International's diagnostics pipeline is in full swing and demand for our analytical services is racing ahead.

I would like to take this opportunity to thank our loyal clients and strategic partners for your continued support which is enabling Proteomics International to grow from strength to strength.

This quarter has seen the licensing of PromarkerD into major markets, the USA and Mexico, and record sales from analytical services for biosimilars and pharmacokinetic testing of clinical trials.

Our team profile this time features Dr Tammy Casey, who has now worked with Proteomics International for over ten years, and exemplifies our expert scientists who continue to deliver world leading R&D.

In the coming months our team will again visit India as we highlight our analytical services in biosimilars QC and stability testing for the world's leading manufacturer of generic drugs. Please contact us if you would like to organise a meeting.

With increasing recognition of the power of the Promarker™ technology, growing revenue streams, and the highly successful capital raising last quarter, Proteomics International is now ideally placed for a bumper 2019 financial year.

Richard Lipscombe, PhD
Managing Director

IN THIS ISSUE

- New licence deals for PromarkerD in USA and Mexico**
- European PromarkerD patent granted**
- PromarkerD on the ABC radio**
- Proteomics at ADA Diabetes Conference**
- Scientific Letter published**
- Team profile
Dr Tammy Casey:
*Research Scientist***
- Escalating demand for analytical services**

PromarkerD commercialisation ramps up: New licence deals

PromarkerD in the USA

Proteomics International signed a deal to launch its PromarkerD predictive test for diabetic kidney disease in the USA. The test will be offered to patients through a partnership with precision medicine and diagnostic services company PrismHealthDx (PHDx), who will launch the LDT version of PromarkerD in its specialist certified laboratories. This version permits fast adoption of a new test in advanced markets.

PHDx will launch PromarkerD nationally making the test available to the more than 30 million people across America living with diabetes, with first sales anticipated to be in two to four months. Proteomics International will receive a royalty on all tests sold. [\[Full article\]](#)



Laboratory Developed Test (LDT)

Certified laboratories can carry out PromarkerD analysis using an LDT. In an LDT, specialised laboratories use mass spectrometers to measure the protein fingerprint in the patient's blood. The data is then sent to the PromarkerD hub for processing and diagnosis.

PromarkerD
CHANGING LIVES
www.PromarkerD.com

PromarkerD is the first test able to predict the onset of diabetic kidney disease, and has the potential to save lives and healthcare system billions of dollars in treatment and dialysis costs. In peer-reviewed clinical studies PromarkerD predicted a decline in kidney function up to four years in advance.

PromarkerD in Mexico

Proteomics International signed a licence agreement with Patia BioPharma for Mexico where diabetes is responsible for one in seven deaths, killing more people than cancer. Patia BioPharma is a Mexican biotech company focused on promoting personalised preventive medicine across Latin America. The licence is again for the LDT version of PromarkerD, and Proteomics International will receive a royalty on all tests sold.

Mexico has one of the highest rates of diabetes in the world, with 13 million adults suffering from the condition. In 2016 the Mexican health ministry declared the diabetes epidemic a national health emergency. Through Patia's network, PromarkerD will initially be introduced to private hospitals and private clinics, and then expanded into government hospitals. First sales are anticipated to be in three to five months. [\[Full article\]](#)

European PromarkerD patent granted for diabetic kidney disease

Proteomics International continued to strengthen its intellectual property position with the grant of a patent for PromarkerD in the major European countries of Britain, Germany, France, Italy, Spain and Turkey. The patent covers more than 400 million people across the six countries, or 5% of the global population. The European patent came into effect on 21 March 2018 and will extend until 20 September 2031. It complements patents already granted in the USA, Australia, Japan, Russia, Singapore and China. [\[Full article\]](#)



New test for diabetes patients can measure risk of chronic kidney disease

Friday 4 May 2018 8:48AM (view full episode)

Half a billion people worldwide now have diabetes and the condition is a major risk factor for chronic kidney failure.

Now, researchers in Perth have developed a test which is able to predict how likely it is for a person with diabetes to develop chronic kidney disease.

IMAGE: DIABETES PATIENTS ARE AT AN INCREASED RISK OF KIDNEY DISEASE. (ABC NEWS: BRIDGET BRENNAN)

PromarkerD on the ABC radio

Proteomics International was featured on the radio with The Naked Scientist talking about the company's pioneering test for diabetic kidney disease – PromarkerD. [ABC Radio](#)

Key Opinion Leader (KOL) Engagement

The company attended the American Diabetes Association 78th Scientific Sessions (Orlando, USA) and will continue to engage with industry KOLs to help drive the adoption of PromarkerD in key markets around the world. [\[Full article\]](#)

Scientific Letter in Cellular & Molecular Immunology

Proteomics International has recently published a Letter to the Editor titled "Apoptosis inhibitor of macrophage and diabetic kidney disease". This letter commented on a review article published in January 2018, supporting the role of PromarkerD biomarkers in diabetic kidney disease.

Davis TME, Peters KE, Lipscombe R. Apoptosis inhibitor of macrophage and diabetic kidney disease. Cell Mol Immunol 2018. [\[Article\]](#)

Team Profile

Dr Tammy Casey: Research Scientist

Dr Tammy Casey joined Proteomics International in 2008 and has a key role in the discovery and development of the company's flagship PromarkerD test. With her expertise in the Promarker™ biomarker discovery platform, Tammy currently oversees the technical development of other diagnostic research programs from the company pipeline, including endometriosis and mesothelioma.

Tammy graduated with a PhD in Biochemistry at the University of Western Australia and gained experience in a wide range of proteomic techniques while undertaking Postdoctoral research at the University of Western Australia and the University of Leeds.



Escalating demand for analytical services

Proteomics International's analytical business grew strongly in the fourth quarter exemplified by the recently announced contract with BiosanaPharma for biosimilars (generic protein drugs) quality control testing. The partnership with Linear Clinical Research for pharmacokinetic (PK) testing for clinical trials also started contributing strongly to sales with the completion of the first PK studies within Proteomics International's laboratories. [\[Full article\]](#)

PROTEOMICS – FAST FACT PANEL

COMPANY CONTACTS

Dr Richard Lipscombe
Managing Director

Mr Chuck Morrison
Head of Business Development

Mr Shane Herbert
Customers Services Manager

Dr Pearl Tan
Chief Operating Officer

Dr Scott Bringans
Research Manager

Susan Fitzpatrick-Napier
Media Contact

AGENTS

India

Proteomics International – India
www.proteomicsindia.com
info-india@proteomics.com.au
P: + 91 8527 699 192

Malaysia/ Indonesia/ Thailand

Apical Scientific Sdn. Bhd.
www.apicalscientific.com
info@apicalscientific.com
P: + 603 8943 3252

Singapore

Axil Scientific Pte Ltd
www.axilscientific.com
peptide@axilscientific.com
P: + 65 6775 7318

Japan

Leave a Nest Co. Ltd
www.leaveanest.com
info@leaveanest.com
P: + 81 3 6277 8041

Hong Kong/ China

Asia Bio Channel Limited
www.asiabiochannel.com
bcoissac@asiabiochannel.com
P: + 852 9845 4791

Latin America

LinkPharma LLC
www.linkpharma.co
customerservice@linkpharmaus.com
P: +1 813 319 3972

Listing

Australian Securities Exchange

Stock Code

ASX: PIQ

Cash Position

A\$2.5 million (30/06/2018)

Issued Capital – Ordinary shares

80.1 million

Market Capitalisation based on share price of 28 cents

A\$22.4 million

Proteomics International is a wholly owned subsidiary of Proteomics International Laboratories Limited (ASX: PIQ)

FOR FURTHER INFORMATION PLEASE CONTACT:

Proteomics International Laboratories Limited

 +61 8 9389 1992

 info@proteomics.com.au (general)
bd@proteomics.com.au (business development)

 www.proteomics.com.au
www.proteomicsinternational.com

 QEII Medical Centre
6 Verdun Street, Nedlands
Perth WA 6009 Australia

Forward looking statement

Any forward looking statements in this newsletter have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors many of which are outside Proteomics International Laboratories Limited's control. Important factors that could cause actual results to differ materially from any assumptions or expectations expressed or implied in this newsletter include known and unknown risks. As actual results may differ materially to any assumptions made in this newsletter, you are urged to view any forward looking statements contained in this newsletter with caution. This newsletter should not be relied on as a recommendation or forecast by Proteomics International Laboratories Limited, and should not be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.